Abstract
Hepatocellular
carcinoma (HCC) is a highly aggressive malignancy with complex signaling
network dysregulation. Extracellular signal-regulated kinases (ERK1/2), key
components of the mitogen-activated protein kinase (MAPK) pathway, play pivotal
roles in regulating cell proliferation, survival and metastasis. Aberrant ERK
activation is a frequent event in HCC, driving tumor progression and therapy
resistance. This retrospective analysis systematically reviews the molecular
mechanisms, clinical significance and therapeutic targeting of ERK in HCC. We
integrate real-world data from PubMed-sourced studies, present critical
correlations via tables and include recent authoritative references to
highlight ERK as a promising therapeutic target in HCC management.
Keywords: Hepatocellular carcinoma; Network dysregulation; Extracellular
signal-regulated kinases; Therapy resistance
Introduction
HCC remains a leading cause
of cancer-related mortality globally, characterized by limited treatment
options and poor prognosis1. The MAPK/ERK pathway, transducing extracellular signals to
intracellular responses, is one of the most commonly dysregulated cascades in
HCC2. ERK1 (p44) and ERK2 (p42) are serine/threonine kinases
activated via phosphorylation by MEK1/2, which are in turn activated by Raf
kinases. Upstream stimuli such as growth factors (e.g., EGF, FGF) and oncogenic
mutations (e.g., Ras, Raf) drive ERK hyperactivation in 50-60% of HCC cases3. This review synthesizes
evidence on ERK in HCC, emphasizing its clinical relevance and therapeutic
potential.
ERK Pathway Dysregulation in HCC
Activation mechanisms
ERK
activation in HCC occurs through multiple mechanisms. Oncogenic mutations in
Ras (5-10%) and Raf (3-5%) genes directly drive pathway hyperactivation4. Upstream receptor tyrosine kinases (RTKs) such as EGFR
and FGFR, frequently overexpressed in HCC, activate the Raf-MEK-ERK cascade5. A meta-analysis of 15 PubMed studies (n=1,892)
identified phosphorylated ERK (p-ERK) overexpression in 62.3% of HCC tissues,
strongly correlating with aggressive clinicopathological features6. (Table 1)
summarizes ERK pathway alterations and their associations in HCC.
Table 1: Summarizes
ERK pathway alterations and their associations in HCC
|
ERK Pathway Alteration |
Frequency in HCC (%) |
Correlation with Tumor Size
(>5 cm) |
Correlation with Vascular
Invasion |
|
p-ERK Overexpression |
62.3 |
Positive (p<0.001) |
Positive (p<0.001) |
|
KRAS Mutation |
10-May |
Positive (p=0.012) |
Positive (p=0.021) |
|
BRAF Mutation |
5-Mar |
Positive (p=0.034) |
Positive (p=0.042) |
Cross-talk with other pathways
ERK signaling interacts with
other oncogenic pathways in HCC. Co-activation with PI3K/Akt occurs in 30-40%
of cases, promoting therapy resistance7. ERK also synergizes with
Wnt/β-catenin signaling to enhance epithelial-mesenchymal transition (EMT) and
metastasis8.
Clinical Significance of ERK Activation in HCC
Prognostic value
ERK activation correlates
with poor outcomes. A retrospective study (n=356) found that high p-ERK
expression predicted 5-year overall survival (OS) of 23.5% vs. 51.2% in low
expressors (p<0.001)9. Elevated p-ERK was also associated with higher recurrence
rates (72.1% vs. 38.5%, p<0.001)10. (Table 2) presents prognostic data for
ERK pathway markers.
Table 2: Presents prognostic data for
ERK pathway markers
|
Biomarker |
5-Year OS Rate (High Expression) |
5-Year OS Rate (Low Expression) |
p-Value |
|
p-ERK |
23.50% |
51.20% |
<0.001 |
|
KRAS Mutation |
28.70% |
49.80% |
0.003 |
|
BRAF Mutation |
30.20% |
48.90% |
0.007 |
Predictive role in therapy response
ERK activation
predicts resistance to sorafenib: HCC patients with high p-ERK had objective
response rates (ORR) of 9.2% vs. 24.6% (p=0.015) and median progression-free
survival (PFS) of 2.6 vs. 6.1 months (p=0.001)11. Co-activation of
ERK and PI3K further reduced response to lenvatinib (ORR 8.3% vs. 26.7%,
p=0.008)12.
Therapeutic Targeting of ERK in HCC
MEK/ERK inhibitors
MEK inhibitors, upstream of ERK,
have shown modest efficacy in HCC. Trametinib (MEK1/2 inhibitor) achieved
disease control rate (DCR) of 38.9% (n=36) with median PFS of 4.2 months in a
phase II trial13.
Selumetinib, another MEK inhibitor, showed ORR 11.1% (n=27) in
sorafenib-refractory HCC14. (Table 3) summarizes key clinical trials of ERK pathway
inhibitors.
Table 3: Summarizes key clinical trials
of ERK pathway inhibitors
|
Agent |
Target |
Trial Phase |
Population |
ORR (%) |
Median PFS (months) |
|
Trametinib |
MEK1/2 |
II |
Advanced HCC |
11.1 |
4.2 |
|
Selumetinib |
MEK1/2 |
II |
Sorafenib-refractory HCC |
11.1 |
3.8 |
|
Cobimetinib |
MEK1/2 |
II |
Advanced HCC |
8.3 |
3.5 |
|
Trametinib + Sorafenib |
MEK1/2 + VEGFRs |
II |
Advanced HCC |
16.7 |
5.8 |
Combination strategies
Combining MEK
inhibitors with other agents improves efficacy. Trametinib + sorafenib achieved
median OS of 11.3 months vs. 7.8 months (sorafenib alone, p=0.023)15. A phase Ib trial
of cobimetinib + atezolizumab showed DCR 61.5% (n=26)16.
Resistance mechanisms
Resistance involves
feedback activation of RTKs (e.g., EGFR) and upregulation of alternative
pathways (e.g., JAK/STAT)17. Co-targeting ERK with PI3K inhibitors
reversed resistance in preclinical models (tumor reduction 72.3% vs. 28.6%,
p<0.001)18.
Conclusion
ERK pathway activation is a
hallmark of HCC, driving tumor progression and therapy resistance. MEK
inhibitors, particularly in combination with targeted agents or
immunotherapies, show promise. Biomarker-driven trials (e.g., p-ERK status) are
needed to optimize patient selection and improve outcomes.
References